Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
33
BCTX Quote, Financials, Valuation and Earnings
Last price:
$4.10
Seasonality move
:
2.2%
Day range:
$3.94 - $4.14
52-week range:
$3.60 - $98.20
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.95x
Volume:
112K
Avg. volume:
215.8K
1-year change:
-88.64%
Market cap:
$29.4M
Revenue:
--
EPS (TTM):
-$27.63
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BCTX
BriaCell Therapeutics Corp.
|
$2.1M | -- | -- | -- | $95.00 |
|
ACHV
Achieve Life Sciences, Inc.
|
-- | -$0.30 | -- | -17.98% | $14.75 |
|
CEOS
CeCors, Inc.
|
-- | -- | -- | -- | -- |
|
HRAL
Hear AtLast Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
PHBI
Pharmagreen Biotech, Inc.
|
-- | -- | -- | -- | -- |
|
VERO
Venus Concept, Inc.
|
$14.5M | -$0.92 | -3.5% | -54.23% | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BCTX
BriaCell Therapeutics Corp.
|
$4.10 | $95.00 | $29.4M | -- | $0.00 | 0% | -- |
|
ACHV
Achieve Life Sciences, Inc.
|
$3.23 | $14.75 | $176.9M | -- | $0.00 | 0% | -- |
|
CEOS
CeCors, Inc.
|
$0.0045 | -- | $1.3M | -- | $0.00 | 0% | 0.63x |
|
HRAL
Hear AtLast Holdings, Inc.
|
$0.0004 | -- | $180.6K | -- | $0.00 | 0% | 30.36x |
|
PHBI
Pharmagreen Biotech, Inc.
|
$0.0015 | -- | $752.2K | -- | $0.00 | 0% | 0.29x |
|
VERO
Venus Concept, Inc.
|
$0.30 | -- | $567.1K | -- | $0.00 | 0% | 0.01x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BCTX
BriaCell Therapeutics Corp.
|
-- | -1.713 | -- | 10.10x |
|
ACHV
Achieve Life Sciences, Inc.
|
41% | 3.656 | 5.65% | 4.01x |
|
CEOS
CeCors, Inc.
|
-- | -11.917 | -- | -- |
|
HRAL
Hear AtLast Holdings, Inc.
|
-1327.89% | -0.919 | 1626.73% | 0.00x |
|
PHBI
Pharmagreen Biotech, Inc.
|
-2.93% | 2.197 | 24.12% | 0.00x |
|
VERO
Venus Concept, Inc.
|
92.44% | 1.394 | 689.6% | 0.48x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BCTX
BriaCell Therapeutics Corp.
|
-$26.7K | -$7.5M | -207.89% | -207.89% | -- | -$8M |
|
ACHV
Achieve Life Sciences, Inc.
|
-$57K | -$14.7M | -149.5% | -213.5% | -- | -$18M |
|
CEOS
CeCors, Inc.
|
-- | -- | -- | -- | -- | -- |
|
HRAL
Hear AtLast Holdings, Inc.
|
-$8.6K | -$58.9K | -- | -- | -1132.69% | -$21.3K |
|
PHBI
Pharmagreen Biotech, Inc.
|
-- | -$1.1M | -- | -- | -32.83% | -$3.8K |
|
VERO
Venus Concept, Inc.
|
$8.8M | -$9.5M | -129.08% | -1236.95% | -68.93% | -$4.9M |
BriaCell Therapeutics Corp. vs. Competitors
-
Which has Higher Returns BCTX or ACHV?
Achieve Life Sciences, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of --. BriaCell Therapeutics Corp.'s return on equity of -207.89% beat Achieve Life Sciences, Inc.'s return on equity of -213.5%.
Company Gross Margin Earnings Per Share Invested Capital BCTXBriaCell Therapeutics Corp.-- -$2.58 $30.2M ACHVAchieve Life Sciences, Inc.-- -$0.28 $36.5M -
What do Analysts Say About BCTX or ACHV?
BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 3558.54%. On the other hand Achieve Life Sciences, Inc. has an analysts' consensus of $14.75 which suggests that it could grow by 356.66%. Given that BriaCell Therapeutics Corp. has higher upside potential than Achieve Life Sciences, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than Achieve Life Sciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCTXBriaCell Therapeutics Corp.1 0 0 ACHVAchieve Life Sciences, Inc.5 0 0 -
Is BCTX or ACHV More Risky?
BriaCell Therapeutics Corp. has a beta of 1.304, which suggesting that the stock is 30.414% more volatile than S&P 500. In comparison Achieve Life Sciences, Inc. has a beta of 1.957, suggesting its more volatile than the S&P 500 by 95.741%.
-
Which is a Better Dividend Stock BCTX or ACHV?
BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Achieve Life Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Achieve Life Sciences, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCTX or ACHV?
BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Achieve Life Sciences, Inc. quarterly revenues of --. BriaCell Therapeutics Corp.'s net income of -$7.3M is higher than Achieve Life Sciences, Inc.'s net income of -$14.7M. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Achieve Life Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus -- for Achieve Life Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCTXBriaCell Therapeutics Corp.-- -- -- -$7.3M ACHVAchieve Life Sciences, Inc.-- -- -- -$14.7M
-
Which has Higher Returns BCTX or CEOS?
CeCors, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of --. BriaCell Therapeutics Corp.'s return on equity of -207.89% beat CeCors, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCTXBriaCell Therapeutics Corp.-- -$2.58 $30.2M CEOSCeCors, Inc.-- -- -- -
What do Analysts Say About BCTX or CEOS?
BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 3558.54%. On the other hand CeCors, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BriaCell Therapeutics Corp. has higher upside potential than CeCors, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than CeCors, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCTXBriaCell Therapeutics Corp.1 0 0 CEOSCeCors, Inc.0 0 0 -
Is BCTX or CEOS More Risky?
BriaCell Therapeutics Corp. has a beta of 1.304, which suggesting that the stock is 30.414% more volatile than S&P 500. In comparison CeCors, Inc. has a beta of -0.003, suggesting its less volatile than the S&P 500 by 100.33%.
-
Which is a Better Dividend Stock BCTX or CEOS?
BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CeCors, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. CeCors, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCTX or CEOS?
BriaCell Therapeutics Corp. quarterly revenues are --, which are larger than CeCors, Inc. quarterly revenues of --. BriaCell Therapeutics Corp.'s net income of -$7.3M is higher than CeCors, Inc.'s net income of --. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while CeCors, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 0.63x for CeCors, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCTXBriaCell Therapeutics Corp.-- -- -- -$7.3M CEOSCeCors, Inc.0.63x -- -- --
-
Which has Higher Returns BCTX or HRAL?
Hear AtLast Holdings, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of -5751.92%. BriaCell Therapeutics Corp.'s return on equity of -207.89% beat Hear AtLast Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCTXBriaCell Therapeutics Corp.-- -$2.58 $30.2M HRALHear AtLast Holdings, Inc.-165.39% -$0.00 -$250.6K -
What do Analysts Say About BCTX or HRAL?
BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 3558.54%. On the other hand Hear AtLast Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BriaCell Therapeutics Corp. has higher upside potential than Hear AtLast Holdings, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than Hear AtLast Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCTXBriaCell Therapeutics Corp.1 0 0 HRALHear AtLast Holdings, Inc.0 0 0 -
Is BCTX or HRAL More Risky?
BriaCell Therapeutics Corp. has a beta of 1.304, which suggesting that the stock is 30.414% more volatile than S&P 500. In comparison Hear AtLast Holdings, Inc. has a beta of 0.395, suggesting its less volatile than the S&P 500 by 60.537%.
-
Which is a Better Dividend Stock BCTX or HRAL?
BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Hear AtLast Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Hear AtLast Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCTX or HRAL?
BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Hear AtLast Holdings, Inc. quarterly revenues of $5.2K. BriaCell Therapeutics Corp.'s net income of -$7.3M is lower than Hear AtLast Holdings, Inc.'s net income of -$299.1K. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Hear AtLast Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 30.36x for Hear AtLast Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCTXBriaCell Therapeutics Corp.-- -- -- -$7.3M HRALHear AtLast Holdings, Inc.30.36x -- $5.2K -$299.1K
-
Which has Higher Returns BCTX or PHBI?
Pharmagreen Biotech, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of -32.19%. BriaCell Therapeutics Corp.'s return on equity of -207.89% beat Pharmagreen Biotech, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital BCTXBriaCell Therapeutics Corp.-- -$2.58 $30.2M PHBIPharmagreen Biotech, Inc.-- -$0.00 -$9.1M -
What do Analysts Say About BCTX or PHBI?
BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 3558.54%. On the other hand Pharmagreen Biotech, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that BriaCell Therapeutics Corp. has higher upside potential than Pharmagreen Biotech, Inc., analysts believe BriaCell Therapeutics Corp. is more attractive than Pharmagreen Biotech, Inc..
Company Buy Ratings Hold Ratings Sell Ratings BCTXBriaCell Therapeutics Corp.1 0 0 PHBIPharmagreen Biotech, Inc.0 0 0 -
Is BCTX or PHBI More Risky?
BriaCell Therapeutics Corp. has a beta of 1.304, which suggesting that the stock is 30.414% more volatile than S&P 500. In comparison Pharmagreen Biotech, Inc. has a beta of 1.914, suggesting its more volatile than the S&P 500 by 91.414%.
-
Which is a Better Dividend Stock BCTX or PHBI?
BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharmagreen Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Pharmagreen Biotech, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCTX or PHBI?
BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Pharmagreen Biotech, Inc. quarterly revenues of $3.4M. BriaCell Therapeutics Corp.'s net income of -$7.3M is lower than Pharmagreen Biotech, Inc.'s net income of -$1.1M. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Pharmagreen Biotech, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 0.29x for Pharmagreen Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCTXBriaCell Therapeutics Corp.-- -- -- -$7.3M PHBIPharmagreen Biotech, Inc.0.29x -- $3.4M -$1.1M
-
Which has Higher Returns BCTX or VERO?
Venus Concept, Inc. has a net margin of -- compared to BriaCell Therapeutics Corp.'s net margin of -163.68%. BriaCell Therapeutics Corp.'s return on equity of -207.89% beat Venus Concept, Inc.'s return on equity of -1236.95%.
Company Gross Margin Earnings Per Share Invested Capital BCTXBriaCell Therapeutics Corp.-- -$2.58 $30.2M VEROVenus Concept, Inc.64% -$12.14 $35.8M -
What do Analysts Say About BCTX or VERO?
BriaCell Therapeutics Corp. has a consensus price target of $95.00, signalling upside risk potential of 3558.54%. On the other hand Venus Concept, Inc. has an analysts' consensus of -- which suggests that it could grow by 38412.35%. Given that Venus Concept, Inc. has higher upside potential than BriaCell Therapeutics Corp., analysts believe Venus Concept, Inc. is more attractive than BriaCell Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings BCTXBriaCell Therapeutics Corp.1 0 0 VEROVenus Concept, Inc.0 1 0 -
Is BCTX or VERO More Risky?
BriaCell Therapeutics Corp. has a beta of 1.304, which suggesting that the stock is 30.414% more volatile than S&P 500. In comparison Venus Concept, Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.188%.
-
Which is a Better Dividend Stock BCTX or VERO?
BriaCell Therapeutics Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Venus Concept, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BriaCell Therapeutics Corp. pays -- of its earnings as a dividend. Venus Concept, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BCTX or VERO?
BriaCell Therapeutics Corp. quarterly revenues are --, which are smaller than Venus Concept, Inc. quarterly revenues of $13.8M. BriaCell Therapeutics Corp.'s net income of -$7.3M is higher than Venus Concept, Inc.'s net income of -$22.5M. Notably, BriaCell Therapeutics Corp.'s price-to-earnings ratio is -- while Venus Concept, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BriaCell Therapeutics Corp. is -- versus 0.01x for Venus Concept, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BCTXBriaCell Therapeutics Corp.-- -- -- -$7.3M VEROVenus Concept, Inc.0.01x -- $13.8M -$22.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 34x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.6T
P/E Ratio: 27x
Alerts
Buy
51
AAOI alert for Apr 3
Applied Optoelectronics, Inc. [AAOI] is up 20.3% over the past day.
Buy
59
SBAC alert for Apr 3
SBA Communications Corp. [SBAC] is up 18.96% over the past day.
Buy
55
VSAT alert for Apr 3
ViaSat, Inc. [VSAT] is up 18.73% over the past day.
